Articles tagged with Cancer Medication
Researchers found that identifying patients with a small number of tumor cells harboring an overabundance of MET even before treatment can produce longer remissions when treated with combination drugs. This suggests that targeting these cells with additional drugs may be beneficial in preventing resistance.
The study analyzed data from 15 trials involving 3,452 women, finding that chemoradiotherapy improved survival rates compared to radiotherapy alone. This treatment also reduced the chance of cancer recurrence and spread.
Researchers at Loyola Medicine found that sun damage silences protein kinase C gene, allowing cancerous cells to grow and divide unchecked. The study could lead to development of new drugs to shrink tumors.
Researchers have found that an anti-Alzheimer's drug can halt the growth of Barrett's oesophagus and even destroy mutant tissue, providing a potential cure for oesophageal cancer. The study, published in Disease Models & Mechanisms, offers new hope for therapy in heartburn-related cancer.
A new study has found that patients with specific oncogenic rearrangements of the anaplastic lymphoma kinase (ALK) gene in their tumors respond significantly to an ALK-inhibitor therapy. The study suggests a paradigm shift in cancer drug development, allowing for more targeted treatments.
Researchers found that decitabine increased activity of genes in cancer cells, leading to complete responses and improved survival times. The study suggests decitabine as a potential first-line treatment for older leukemia patients with limited options.
Researchers at Karolinska Institutet have identified a new way to block blood vessel formation and halt tumour growth in mice. The discovery focuses on the ALK1 receptor, which is activated by TGF-β proteins that stimulate angiogenesis in tumours.
Researchers found a new drug, bortezomib, effective in killing gastrointestinal stromal tumor cells through two mechanisms, increasing apoptosis and suppressing KIT enzyme production. The study supports moving forward with clinical trials to assess its benefits and risks as a secondary treatment for imatinib-resistant GIST patients.
Researchers found that cancer drugs targeting PDGFR can impair the heart's ability to respond to stress, increasing risk of heart failure. The study suggests aggressive control of high blood pressure may reduce cardiac toxicity caused by these agents.
Researchers question the safety of gene therapy targeting I-1c in treating heart failure after finding it can cause abnormal heartbeats and sudden death. Additionally, a study reveals that certain anticancer drugs can cause heart failure by triggering PDGFR-beta signaling in heart muscle cells.
A new investigational agent YC137 was found to restore sensitivity of breast cancer cells to treatment by fulvestrant, a commonly used drug for estrogen-receptor-positive metastatic breast cancer. The study suggests that using an agent that can hit multiple Bcl2 proteins will be more effective in overcoming tumor resistance.
A team of researchers developed a 'nano cocktail' consisting of two nanomaterials that work together to locate, adhere to, and kill cancerous tumors. The system uses gold nanorods to accumulate in tumors and then sends in a second nanoparticle type coated with a targeting molecule specific for the heat-treated tumor.
Researchers at Georgetown Lombardi Comprehensive Cancer Center report a significant advance in personalized medicine using a new chip that examines hundreds of genetic mutations. The chip, called DMET, could replace highly-specialized and labor-intensive genotyping tools, accelerating cancer research and treatment.
A team of researchers has discovered how a cancer drug works, revealing its potential to treat various cancers and improve efficacy. The breakthrough could lead to the design of new cancer drugs that work on the same principle as cordycepin.
A study found that melanoma incidence rates increased 2.4 percent per year among white non-Hispanic individuals, while Hispanic and black patients had more advanced melanoma at diagnosis, suggesting the need for targeted education and screening campaigns to address disparities in melanoma outcomes
A study published in the Journal of the National Cancer Institute found that urinary tract cancer is associated with the use of Chinese herbal products containing aristolochic acid. The risk increased with higher doses and was independent of arsenic exposure. The authors recommend continued surveillance and monitoring of patients who h...
Researchers found that restricting glucose intake extends normal human cell lifespan and impairs precancerous cell growth through epigenetic control. The study, published in the FASEB Journal, could lead to novel approaches to extend human lifespan and prevent cancer.
Key advances in DNA sequencing technology and gene mutations have identified candidate cancer genes that contribute to colorectal cancer. The study also highlights the importance of understanding biological pathways deregulated in colon cancer, which can form the basis of new therapeutic agents.
A group of heart drugs, cardiac glycosides, have been found to be effective against human colon cancer cells, with varying degrees of sensitivity. The findings suggest that these heart drugs could potentially improve colon cancer outcomes when used alone or in combination with conventional chemotherapy.
Researchers at Purdue University have developed nanoprobes that deliver cancer drugs directly to tumor cells, reducing damage to healthy cells. The nanoprobes mimic the natural delivery system of endosomes and can track their distribution within cells.
Postmenopausal women taking antidepressants may be at higher risk of stroke and death compared to those not taking the medication. Researchers emphasize the need for individualized risk assessment and further study to determine the exact association.
Researchers at Tel Aviv University have discovered a new mechanism for DNA packaging that affects RNA splicing, leading to differences in protein production. This finding has significant implications for disease diagnosis and treatment, including the development of innovative drug therapies.
A Johns Hopkins-led study finds that while the US has more accessible high-priced cancer drugs, many patients in both countries face financial obstacles due to high out-of-pocket costs. The UK system is considered fairer, but both nations struggle with rationing and end-of-life care decisions.
A new hybrid agent, T-DM1, has shown promising results in a Phase 2 clinical trial for metastatic HER2-positive breast cancer. The compound shrunk tumors by 30% or more in 40% of women with confirmed HER2-positive cancers, and had a total clinical benefit rate of approximately 53%.
A new study presents a promising approach to re-sensitize breast cancer to standard therapy after it becomes resistant. The treatment combination of an aromatase inhibitor and sorafenib shows encouraging responses in 20% of post-menopausal women with metastatic breast cancer, offering a potential new treatment option.
Researchers have discovered a molecular mechanism that can be arrested in human cancer cells, causing them to die without affecting normal body cells. The compound, initially developed for stroke prevention, was found to be effective against breast cancer cells with no toxicity to normal cells.
A new cancer drug, R-Roscovitine, has been found to kill eosinophils that exacerbate asthma symptoms. Researchers believe this could offer an alternative treatment for resistant asthma patients.
Researchers at the University of Florida have found a way to use reduced dosages of the chemotherapy drug TMZ to achieve better results against colon cancer cells. By combining TMZ with a small molecule, they were able to disable the ability of tumor cells to repair DNA damage.
A phase III trial showed that defibrotide was markedly more effective than standard treatment in post-stem cell transplant patients with hepatic veno-occlusive disease. The mortality rate 100 days after transplant was reduced to 62 percent for patients receiving defibrotide.
Researchers identified a critical pathway that stimulates Mdm2 production, binding to and extinguishing tumor suppressors like p53. Preventing Mdm2's destruction is crucial to preventing cancer from spreading within the body.
Dr. Matthew Levy has received $700,000 in Stand Up To Cancer funding to develop self-guiding drugs that target only cancer cells, reducing serious side effects of current therapies.
Researchers at Dana-Farber Cancer Institute found that midostaurin, a kinase inhibitor targeting FLT3 cell receptor, combined with chemotherapy reduced circulating leukemia cells in AML patients. Complete responses occurred in 80% of patients with mutated FLT3, and high survival rates were observed one and two years after treatment.
A phase II clinical trial shows that carfilzomib induces a response in 45% of patients with relapsed or resistant multiple myeloma, reducing neuropathy side effects. The drug also demonstrates good tolerability and dose flexibility.
A randomised trial found that medroxyprogesterone acetate is significantly more effective than venlafaxine at reducing hot flushes in men treated with androgen suppression therapy. Cyproterone acetate was also effective, but medroxyprogesterone is recommended as the standard treatment due to its fewer side effects.
Early clinical trial results show bortezomib-based therapy improves control of graft-versus-host disease and immune system recovery. The treatment was safe with little toxicity, and immune cell reconstitution was significantly improved in the early post-transplant period.
Researchers found that omacetaxine achieved durable responses in CML patients with the T315I mutation, who have limited treatment options. The injectable drug works by a different mechanism than current therapies and has shown promise for expanded use.
A non-absorbed oral co-polymer therapy under development by Midway Pharmaceuticals demonstrates ability to protect against radiation damage and prevent lethal bacterial infections in animal models. The compound, PEG 15-20, may provide new way to prevent serious GI side effects of radiation in cancer patients.
A U-M study found that only 6% of high-risk women were likely to take tamoxifen, a drug proven to prevent breast cancer, due to concerns over side effects. The decision aid provided tailored information about the drug's risks and benefits, improving understanding but not changing behavior.
Researchers found a way to turn ineffective cancer drugs into effective fighters using their patented chemical compound, SHetA2. The compound tricks cancer cells into responding to new treatments and undergoing cell suicide without harming normal cells.
Researchers found that Erbitux, a cancer treatment drug, reversed symptoms of Ménétrier's disease in nearly half of patients. The study provides new hope for those suffering from this rare condition.
Researchers have identified a number of proteins that allow them to distinguish between cancer and normal cells with high accuracy. This discovery may lead to the development of drugs specifically targeting these proteins to inhibit their activation.
A new Indiana University School of Medicine study found that involving family members in medical rounds improves care and communication. Families reported increased feelings of inclusion, respect, and a better understanding of their child's care. Participation is voluntary, and family members can ask questions and offer input.
A new compound, PU-H71, has been discovered that may prove to be a powerful target for the treatment of non-Hodgkin's lymphoma. The compound was found to suppress tumor formation in lab testing and animal models.
Researchers at Agios Pharmaceuticals have discovered that the mutated IDH1 gene produces a metabolite called 2-hydroxyglutarate, which contributes to the formation and progression of gliomas. This finding validates cancer metabolism as an approach to identify new ways to treat cancer.
The editorial highlights exaggerated fears and hopes in media coverage of cancer research, such as uncontrolled study results and unwarranted fear from studies. Journalists can alleviate this problem by asking the right questions, highlighting study limitations, and providing data to support claims.
New studies show that morphine can boost tumor-cell proliferation and inhibit the immune response, promoting angiogenesis and cancer metastasis. Shielding lung cancer cells from opiates reduces cell proliferation, invasion, and migration in both cell-culture and mouse models.
Researchers have developed a new mouse variety that approximates human genetic diversity, allowing for more accurate testing of chemotherapeutic drugs. The study aims to reduce the risk of adverse reactions and improve treatment outcomes for cancer patients.
The Tulane Cancer Center is conducting a phase III randomized clinical trial for Alpharadin, an injectable treatment targeting radioactive substance Radium-223. Early trials suggest it may prolong survival for men with bone metastases from prostate cancer.
Researchers successfully delivered high-dose chemotherapy to malignant brain tumors via intra-arterial Avastin, potentially avoiding common side effects of systemic chemotherapy. The innovative technique has shown promising results in early trials and may offer a new treatment option for patients with resistant brain tumors.
Researchers at Karolinska Institutet have identified a paradoxical protein that stimulates stem cell division but prevents cancer growth. The study suggests a potential new treatment using the drug imatinib to prevent colon cancer in high-risk patients.
Researchers at Cornell University College of Veterinary Medicine have discovered that inactivating the Hus1 gene efficiently kills cells lacking p53, a gene mutated in most human cancers. The study provides an important new understanding of cancer cells and their weaknesses.
Researchers discovered that Stapled Peptides can potently and directly inhibit the Notch transcription factor complex, preventing cancer cell proliferation and survival. The findings validate the potential of Stapled Peptides to modulate key intracellular biological targets.
Researchers have devised a new way to disarm the key protein NOTCH, which drives tumor growth. The discovery lays the foundation for a new therapy aimed at critically important transcription factors that could treat various diseases, including multiple types of cancer.
A new study published in Cancer Research found that a potential drug for lung cancer eliminated tumours in 50% of mice and stopped growth and resistance to treatment. The researchers are planning to take the drug into clinical trials to establish its effectiveness for patients with small cell lung cancer.
A new study linked erythropoiesis-stimulating agents (ESAs) to a higher risk of venous thromboembolism in cancer patients. The analysis, published in the Journal of the National Cancer Institute, suggests that ESAs may not be worth the increased risk of blood clots.
A study published in the Journal of the National Cancer Institute found that erythropoiesis-stimulating agents increase the risk of venous thromboembolism in cancer patients. The use of these agents, approved to reduce blood transfusions during chemotherapy, may outweigh benefits due to associated risks.
Researchers at University of Wisconsin-Madison used two FDA-approved drugs to eliminate and prevent cervical cancer in mice. The drugs, which block estrogen's ability to bind to cells, cleared precancerous growths and prevented cancer onset in mice with HPV-positive lesions.
Researchers found that Bortezomib shuts down cellular machines that destroy Runx2, a protein complex that blocks the growth of bone cancer cells. The study suggests that Bortezomib may represent a new treatment option for osteosarcoma, a devastating disease that responds poorly to current chemotherapies.
Researchers at Johns Hopkins University discovered a 1930s gonorrhea medication, acriflavine, that can halt the growth of new blood vessels in cancer cells. By inhibiting HIF-1, a protein essential for tumor growth, acriflavine may one day be incorporated into chemotherapy cocktails to fight cancer.
Researchers at OHSU Knight Cancer Institute have found a combination of radiation therapy and chemotherapy given before prostate removal to be safe and potentially reduce cancer recurrence rates. The treatment regimen resulted in improved outcomes, with clean cancer margins and undetectable PSA levels in patients.